Tandem Diabetes price target lowered to $37 from $39 at Baird

Baird analyst Jeff Johnson lowered the firm’s price target on Tandem Diabetes (TNDM) to $37 from $39 and keeps a Neutral rating on the shares. The firm said Q3 revenue nicely exceeded the Street, although timing benefits for both U.S. supplies and OUS distributor orders partly contributed, with 3Q pump shipments in the U.S. more in line with Baird’s model.